Category Archives: Glucose Monitoring

Novo to Bring Connected Care to Ozempic; New Novo Ph1 Oral Amycretin Trial; Dexcom Moves Manufacturing to Arizona; US House Advances Medicare Obesity Bill; Esperion Enters Purchase Agreement with OMERS

A series of cardiometabolic-related news items have been observed from Novo Nordisk, Dexcom, US House of Representatives, and Esperion. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

EXCLUSIVE: FENIX Interview with CGM Newcomer Allez Health (Part 2)

As promised, FENIX delivers on Part 2 of the exclusive interview with Leif Bowman, the co-founder of Allez Health, an emerging biosensor venture founded by veterans in the CGM space. In case you missed it, Part 1 of the exclusive interview covered insights into Allez’s business philosophy and an early look into the features of its CGM (view here). Below, FENIX provides further details on Allez’s launch timelines, data-sharing strategy, and perspective on the market heavyweights, Dexcom and Abbott.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2024 Key Press Releases (June 24)

On the final day of the ADA 2024 conference, nine cardiometabolic-related news items have been observed from Novo Nordisk, Adipo Therapeutics, Trinity Biotech, Alnylam, Viking, Teva, Teladoc Health, and CHMP. Below, FENIX provides context and analysis for the announcements, including thoughts on the potential FLOW label.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2024 Key Press Releases (June 23)

On the third day of ADA 2024, four cardiometabolic-related news items have been observed from Senseonics, Altimmune, Fractyl Health, and Gan & Lee. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

ADA 2024 Key Press Releases (June 22)

On the second day of ADA 2024, six cardiometabolic-related news items have been observed from Insulet, Medtronic, Terns Pharmaceuticals, MannKind, Tandem, and Altimmune. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Register

Already a member? Log in here

EXCLUSIVE: FENIX Interview with CGM Newcomer Allez Health (Part 1)

To kick off the ADA 2024 conference, FENIX sat down with Leif Bowman, the co-founder of Allez Health, for an in-depth interview on the company’s goal to disrupt the CGM market. Recall, in May 2024, Allez announced it secured $60M in a Series A+ financing round led by Osang Healthcare Co. Ltd and with participation from existing investors (previous FENIX insight). For context, Allez (formerly called Zense-Life; view website) is an emerging biosensor venture founded by veterans in the CGM space. Below, FENIX provides Part 1 of our exclusive interview which includes insight into Allez’s business philosophy as well as an early look into the features of its CGM.

This content is for Read Less members only.
Register

Already a member? Log in here

Omnipod 5 Launch Updates; Zealand Ph1b MAD Petrelintide data; Ypsomed AID Algorithm Approved by FDA; Silence Ph2 siRNA Results; Lilly Fights Compounded Tirzepatide Sales

A series of cardiometabolic-related news items have been observed from Insulet/Dexcom, Zealand, Ypsomed, Silence Therapeutics, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Merck Initiates Ph2a Efinopegdutide Trial in MASH; Lexicon Publishes Cost-Effectiveness Analysis of Inpefa; Novo, Tandem, and Altimmune to Present at ADA 2024

Three cardiometabolic-related news items have been observed: Merck initiated a new Ph2a trial of efinopegdutide in MASH (view CT.gov record); Lexicon Pharmaceuticals published a cost-effective analysis of Inpefa in diabetes and HF (view press release); Novo Nordisk (view press release), Tandem Diabetes Care (view press release), and Altimmune (view press release) announced data presentations at ADA 2024. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

FDA Clears Abbott’s Lingo and Libre Rio CGMs; Lilly Publishes SYNERGY-NASH Results; Teladoc Appoints New CEO

Three cardiometabolic-related news have been observed: Abbott announced FDA cleared its Lingo and new “Libre Rio” CGM systems for OTC (view press release); Lilly announced detailed results from the Ph2 SYNERGY-NASH trial were presented at EASL 2024 (June 5-8; Milan, IT) and published in the NEJM (view press release); and Teladoc appointed Charles Divita, III, as its CEO effective immediately (view press release). Below, FENIX provides highlights and insights for the respective news items, including thoughts on how Lingo and Libre Rio will compete with Dexcom’s Stelo.

This content is for Read Less members only.
Register

Already a member? Log in here

CinRx Raises $73M to Fund its Startups, Including Obesity; Dexcom ONE Reimbursement for T2DM Patients in France; Viking Positive Ph2b Histology MASH Data; Lilly Initiates Ph3 SURMOUNT-ADOLESCENTS-2 Trial

A series of cardiometabolic-related news items have been observed from CinRx Pharma, Dexcom, Viking Therapeutics, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for members only.
Register

Already a member? Log in here